Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains.

作者: Dirlei Nico , Daniele Crespo Gomes , Marcus Vinícius Alves-Silva , Elisangela Oliveira Freitas , Alexandre Morrot

DOI: 10.3389/FIMMU.2014.00189

关键词:

摘要: The Nucleoside hydrolase of Leishmania donovani (NH36) is a phylogenetic marker high homology among parasites. In mice and dog vaccination NH36 induces CD4+ T cell-driven protective response against chagasi infection directed its C-terminal domain (F3). N-terminal vaccines also decreased the footpad lesion caused by amazonensis. We studied basis crossed immune using recombinant generated peptides covering whole sequence saponin for prophylaxis L. F1 (amino acids 1-103) F3 peptide 199-314) enhanced IgG IgG2a anti-NH36 antibodies to similar levels. vaccine induced strongest DTH response, highest proportions NH36-specific CD8+ cells after challenge expression IFN-γ TNF-α. vaccine, on other hand, weaker but significant mild enhancement TNF-α in vivo depletion with anti-CD4 or CD8 monoclonal disclosed that cross-protection amazonensis was mediated cell (75% reduction size lesion) followed (57% lesions). Both were capable inducing long-term cross-immunity. amino acid showed 93% identity NH A34480 which presence completely conserved predicted epitopes domain, differing single acid, domains. identification domains as targets model amazonesis represents rationale development bivalent leishmaniasis.

参考文章(49)
A. C. Kushalappa, Biology and epidemiology Biology and epidemiology.. pp. 13- 80 ,(1989)
D.C. Kaslow, Transmission-Blocking Vaccines Chemical Immunology. ,vol. 80, pp. 287- 307 ,(2002) , 10.1159/000058850
Christopher Dye, The Logic of Visceral Leishmaniasis Control American Journal of Tropical Medicine and Hygiene. ,vol. 55, pp. 125- 130 ,(1996) , 10.4269/AJTMH.1996.55.125
Sylvie Bertholet, Yasuyuki Goto, Lauren Carter, Ajay Bhatia, Randall F. Howard, Darrick Carter, Rhea N. Coler, Thomas S. Vedvick, Steven G. Reed, Optimized subunit vaccine protects against experimental leishmaniasis Vaccine. ,vol. 27, pp. 7036- 7045 ,(2009) , 10.1016/J.VACCINE.2009.09.066
Míriam Maria Costa, Marcos Penido, Mariana Silva Dos Santos, Daniel Doro, Eloísa de Freitas, Marilene Susan Marques Michalick, Gabriel Grimaldi, Ricardo Tostes Gazzinelli, Ana Paula Fernandes, None, Improved Canine and Human Visceral Leishmaniasis Immunodiagnosis Using Combinations of Synthetic Peptides in Enzyme-Linked Immunosorbent Assay PLOS Neglected Tropical Diseases. ,vol. 6, ,(2012) , 10.1371/JOURNAL.PNTD.0001622
Wuxian Shi, Vern L. Schramm, Steven C. Almo, Nucleoside hydrolase from Leishmania major. Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-a crystal structure. Journal of Biological Chemistry. ,vol. 274, pp. 21114- 21120 ,(1999) , 10.1074/JBC.274.30.21114
Claris B. Palatnik de Sousa, Elza M. Gomes, Edilma Paraguai de Souza, Wania R. dos Santos, Sirley R. de Macedo, Linnete V. de Medeiros, Kleber Luz, The FML (Fucose Mannose Ligand) of Leishmania donovani: a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar Revista Da Sociedade Brasileira De Medicina Tropical. ,vol. 29, pp. 153- 163 ,(1996) , 10.1590/S0037-86821996000200008
Ingrid Aguilar-Be, Renata da Silva Zardo, Edilma Paraguai de Souza, Gulnara Patrícia Borja-Cabrera, Miguel Rosado-Vallado, Mirza Mut-Martin, Maria del Rosario García-Miss, Clarisa Beatriz Palatnik de Sousa, Eric Dumonteil, Cross-Protective Efficacy of a Prophylactic Leishmania donovani DNA Vaccine against Visceral and Cutaneous Murine Leishmaniasis Infection and Immunity. ,vol. 73, pp. 812- 819 ,(2005) , 10.1128/IAI.73.2.812-819.2005
Lukasz Kedzierski, Leishmaniasis Vaccine: Where are We Today? Journal of Global Infectious Diseases. ,vol. 2, pp. 177- 185 ,(2010) , 10.4103/0974-777X.62881